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Malignant Hyperthermia 
Chase Contri SRNA 
PATHOPHYSIOLOGY 
Malignant hyperthermia is a hypermetabolic disorder 
caused by mutation of the ryanodine receptor.  More 
specifically it deals with the ryanodine receptor located 
on the major regulatory calcium release channel of the 
sarcoplasmic reticulum of skeletal muscle, known as the 
RYR1 receptor (Hines & Marschall, 2012).  This mutation 
causes an excessive release of calcium from the 
sarcoplasmic reticulum when triggered that leads to 
sustained muscle contraction. The release of calcium is 
much more abundant compared to the body’s abilities to 
remove the calcium from the muscles myoplasm.  This 
causes an increased metabolic state that increases 
oxygen consumption, increases carbon dioxide 
production, increases heat production, increases 
anaerobic metabolism, and decreases ATP stores.  
Calcium is removed and pumped back into the 
sarcoplasmic reticulum by ATP.  ATP stores are depleted 
due to exhaustion of attempting to replace the 
abundance of calcium back into the sarcoplasmic 
reticulum and the binding of calcium to muscle’s 
troponin to elicit contraction.  When ATP stores are 
depleted and oxygen can no longer be utilized, anaerobic 
metabolism takes place leading an acidotic and 
potentially fatal state. 
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• Nitrous Oxide is NOT 
considered a triggereing agent 
and is safe to use for someone 
susceptible for malignant 
hyperthermia. 
 
Figure 1.  Mutation of RY1 receptor causes abundant release 
of calcium from sarcoplasmic reticulum that leads to a 
hypermetabolic state. 
Providers need to determine who 
is susceptible to this disorder in 
order to prevent malignant from 
occurring to begin with.  
Malignant hyperthermia is an 
inherited genetic disorder and is 
considered an autosomal 
dominant trait.  Being autosomal 
dominant means that only one 
parent can carry the gene and still 
pass it along to their offspring.  
Incidence of this gene is 1/10,000 
(Anderson-Pompa et al, 2008). 
 
  A detailed pre-operative 
assessment could possibly reveal a 
family history of the disorder 
which would warrant further pre-
operative evaluation and 
susceptibility to malignant 
hyperthermia.  To determine 
susceptibility, a patient could have 
genome testing done to see if they 
have the trait or undergo a 
caffeine-halothane contracture 
test (CHCT).   
 
Caffeine Halothane Contracture 
Test   
 
• CHCT have been shown to be 
97%-99% sensitive for 
malignant hyperthermia 
(Rosenberg, Antognini, & 
Muldoon, 2002).  The CHCT 
disadvantages include a 
small outpatient surgery 
required for a muscle biopsy, 
only six locations are present 
in the United States that 
provides the test, and it is 




• Genome testing is considered 
less invasive and more 
convenient but only detects 
thirty percent of people at 








Onset of malignant hyperthermia, after 
exposure to these agents, occurs commonly 
within sixty minutes.  Some reports have 
shown a delay of six hours to the occurrence 
of malignant hyperthermia with the use of 













Table 1. Early and Late S/S of Malignant Hyperthermia 
 
Malignant hyperthermia can be a difficult disorder to diagnosis while a patient is in the 
anesthetized state. An anesthetist must be knowledgeable of the early and late signs and 
symptoms of malignant hyperthermia.  Early signs and symptoms can be vague and subtle at 
first and resemble side effects of the rapid and increased calcium release.  The first sign of 
early progression of malignant hyperthermia is hypercarbia.  Hypercarbia can be defined as 
carbon dioxide level above 45 mmHg.  This can be measured by an arterial blood gas analysis 
or through Capnography.  The increase in carbon  dioxide is secondary to increase in oxygen 
consumption.  When the hypercarbia is present, a patient will become tachypneic to 
compensate for the increase in carbon dioxide.  Tachypnea will not be present with a patient 
who is in a paralytic state as during some surgical cases.  In this case carbon dioxide 
monitoring will be crucial.  Tachycardia is another early sign of malignant hyperthermia.  
Tachycardia is present due to the increasing hypoxia, hypercarbia, sympathetic stimulation, 
and catecholamine release that occur during this hypermetabolic state.  Muscle rigidity can 
also be used as an early sign and symptom of malignant hyperthermia due to the sustained 
muscle contraction from the release of calcium.  Masseter and extremity muscles are the 
most common sites for increased rigidity during progressing malignant hyperthermia.  
Muscle rigidity will still occur in these locations even if a patient has received neuromuscular 
blocking drugs (Glahn et al, 2010). 
 
Late signs and symptoms can be more detrimental to the patient as it reflects anaerobic 
metabolism and deterioration. A patient can become extremely acidotic during a malignant 
hypertension crisis. Metabolic acidosis can ensue due to an over production of lactic acidosis 
due to anaerobic metabolism and cellular hypoxia.  Systemic pH can drop dramatically due to 
a combination of hypercarbia and lactic acid production.  Serial arterial blood gasses need to 
be analyzed during a malignant hyperthermia crisis to monitor the disease state.  As the 
patient becomes increasingly acidotic, cells will try to regulate the abundance of hydrogen 
ions through the exchange of potassium.  As a result a patient will become hyperkalemic 
causing cardiac arrhythmias.  Hyperthermia typically is one of the latest symptoms that 
develop during a malignant hyperthermia episode.  Hyperthermia occurs due to a significant 
amount of heat production during sustained muscle contraction and increased ATP 
phosphorylation.  During a malignant hyperthermia crisis, temperatures can rise 1 degree 
Celsius every five minutes and can exceed 43 degrees Celsius (Nagelhout & Plaus, 2014). 
 
If left untreated or identified too late, malignant hyperthermia can lead to overwhelming cell 
death, severe rhabdomyolysis, and life threatening disseminated intravascular coagulation 
(DIC).  Rhabdomyolysis is caused by increase in muscle breakdown and death and the 
release of myoglobin into the bloodstream.  The increase in free myoglobin can cause acute 
kidney injury or failure due to renal tubule blockage.  DIC can occur in the late stages of a 
malignant hyperthermia crisis mainly due to profound hyperthermia.  Hyperthermia causes 
DIC due to a destruction and instability of clotting proteins and when developed, leads to 
poor outcome for the patient.  When DIC has develop during malignant hyperthermia, 
cardiac arrest is fifty times more prevalent and death is ninety times more likely to occur 
(Barash et al, 2013). 
When a patient has been determined to be at 
high risk for malignant hyperthermia either 
from pre-operative testing or previous 
malignant hyperthermia reaction, a safe and 
preventative anesthesia plan is developed by 
the anesthesia provider and nurse.  Steps 
and interventions including in this plan 
include avoidance of the use of halogenated 
agents such as Desflurane, Isoflurane, 
Sevoflurane, and Halothane.  Nitrous Oxide 
has been proven to not be a trigger for 
malignant hyperthermia and is considered 
safe.  There must also be avoidance of the 
use of the depolarizing muscle relaxant 
Succinylcholine. The use of regional or total 
intravenous anesthesia (TIVA) is safe 
anesthetic plans for patients susceptible to 
malignant hyperthermia.  Many institutions 
have anesthesia machines designated 
specifically for susceptible malignant 
hyperthermia patients that have not had any 
volatile agents that could trigger a malignant 
hyperthermia response.  If an institution 
does not have such a machine,  an anesthesia 
machine being used on a susceptible patient 
must have oxygen ran though it for a 
minimum of ten minutes at a rate of ten 
liters per minutes to ensure all volatile 
agents have been flushed out.  Vigilant 
monitoring of these patients is imperative to 
ensure a reaction does not occur or if one 
does, it can be treated promptly 
(Butterworth, Mackey, & Wasnick, 2013). 
Treatment 
The first step is being able to 
recognize and determine that the 
patient is undergoing a reaction 
and to call for help to get the 
entire medical team present and 
aware of the situation.  All 
potential triggers must be 
eliminated and removed from the 
patient.  Dantrolene will be given 
to the patient to reverse the 
progression of malignant 
hyperthermia.  Dantrolene is 
skeletal muscle relaxant by the 
mechanism of inhibiting calcium 
release from the sarcoplasmic 
reticulum.  By inhibiting calcium 
release, the progression of 
malignant hyperthermia can be 
ceased.  The use of Dantrolene for 
the treatment of malignant 
hyperthermia has decreased 
patient mortality from 70% to 5%.  
Dantrolene is given intravenously 
at a dose of 2.5mg/kg to a max 
dose of 10mg/kg until termination 
of malignant hyperthermia crisis. 
Redosing of dantrolene is done 
every six hours for 24 hours to 
prevent reoccurrence of the 
disease process at a dose of 1-2 
mg/kg.  Along with 
pharmacological intervention for 
reversing malignant hyperthermia 
process by decreasing calcium 
release, treatment and 
interventions can be done to help 
control the symptoms of 
malignant hyperthermia; 
hypercarbia, hyperthermia, 
acidosis, hyperkalemia, and 




Extensive and detailed pre-
operative assessment must be 
obtained to determine a patient’s 
susceptibility of the disease in 
order to determine a safe 
anesthetic plan to decrease or 
eliminate risk of malignant 
hyperthermia crisis.  If a crisis 
does occur, the ability to recognize 
malignant hyperthermia will lead 
to faster treatment and 
intervention and decreased 
morbidity and mortality.  The use 
and knowledge of different forms 
of treatment will aid and help 
provide the best possible outcome 
for the patient in the end. 
Introduction 
Although very rare, occurring one out of every 100,000 
anesthesia cases, malignant hyperthermia is a 
hypermetabolic disorder that anesthesia providers screen 
and interrogate patients prior to every case they are 
administering anesthesia. Many research studies about 
anesthesia induced malignant hyperthermia have explored 
new methods of testing for the genetic susceptibility for 
malignant hyperthermia and into hospital based protocols 
when a patient starts to show the signs and symptoms of 
the metabolic disorder. This new knowledge and 
understanding has decreased patient mortality of 
anesthesia induced malignant hyperthermia from eighty 
percent to five percent over the past three decades 
(Rosenberg et al, 2007).   
